Home/Galecto/Dr. Steen Lisby
DS

Dr. Steen Lisby

Chief Scientific Officer

Galecto

Therapeutic Areas

Galecto Pipeline

DrugIndicationPhase
GB1211MASH with liver fibrosisPhase 2b
TD139Idiopathic Pulmonary Fibrosis (IPF)Phase 2/3
GB2064MyelofibrosisPhase 2